发明名称 |
Crystalline form of a 3-phenoxymethylpyrrolidine compound |
摘要 |
The invention provides a crystalline hydrochloride salt of (S)-3-[(S)-1-(4-chlorophenoxy)-2-methylpropyl]pyrrolidine. This invention also provides pharmaceutical compositions comprising the crystalline salt, processes and intermediates for preparing the crystalline salt, and methods of using the crystalline salt to treat diseases. |
申请公布号 |
US8791151(B2) |
申请公布日期 |
2014.07.29 |
申请号 |
US201213720385 |
申请日期 |
2012.12.19 |
申请人 |
Theravance Biopharma R&D IP, LLC |
发明人 |
Saito Daisuke Roland |
分类号 |
A61K31/40;C07D207/08 |
主分类号 |
A61K31/40 |
代理机构 |
|
代理人 |
Hagenah Jeffrey A.;Eberle Shelley |
主权项 |
1. A method of treating a patient that is suffering from attention deficit hyperactivity disorder, comprising administering a therapeutically effective amount of a crystalline salt of (S)-3-[(S)-1-(4-chlorophenoxy)-2-methylpropyl]pyrrolidine and hydrochloric acid in a 1:1 molar ratio, characterized by a powder x-ray diffraction pattern comprising diffraction peaks at 2θ values of 8.78±0.20, 15.26±0.20, 19.08±0.20, 20.36±0.20, 21.50±0.20, and 25.46±0.20. |
地址 |
South San Francisco CA US |